Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082509 | 0.86 | PRPS1 (0.56) | HTR6AVPR1ACNR2CNR1PRPS1 | |
| SCHEMBL2642993 | 0.85 | CNR2 (0.48) | CNR2CPT1ACNR1PRPS1MCL1 | |
| SCHEMBL825141 | 0.83 | HTR6 (0.45) | HTR6AVPR1ACNR2CPT1ACNR1 | |
| SCHEMBL2642659 | 0.83 | CNR2 (0.51) | CNR2CNR1PRPS1ALDH1A1 | |
| SCHEMBL612486 | 0.82 | AVPR1A (0.58) | HTR6AVPR1ACPT1A | |
| SCHEMBL2642676 | 0.82 | KDM4E (0.48) | CNR2CPT1ACNR1ALDH1A1CA1 | |
| SCHEMBL2643380 | 0.82 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL612485 | 0.82 | AVPR1A (0.54) | AVPR1ACNR2CPT1ACNR1MCL1 | |
| SCHEMBL2643935 | 0.82 | PTGDR2 (0.43) | HTR6AVPR1ACNR2CPT1ACNR1 | |
| SCHEMBL7778088 | 0.81 | CNR2 (0.70) | HTR6CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256140-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES | BISSANTZ CATERINA | 2010-10-07 | — | — | US | disclosed |
| US-7803815-B2 | Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1912976-B1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| CN-101268067-A | Indol-3-yl-carbonyl-piperidine-benzimidazole derivatives as V1A receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| EP-1912976-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007009906-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256140-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES | AVPR1A, AVPR2, AVPR1B | HTR6 116/4885AVPR1A 1/4885CNR2 96/4885 |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | AVPR1A, AVPR2, AVPR1B | HTR6 116/4885AVPR1A 1/4885CNR2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.